Get notified when UAMY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (worsened) — Material weakness disclosure persists for second consecutive year with expanded remediation scope but no indication of completion.
UAMY secures $27M defense grant, expands capacity but burns $12M cash amid margin squeeze
Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read
Key Changes
-
high
Q1 2026 operating cash flow negative $12.1M vs negative $1.7M prior year, driven by $9.7M inventory buildup (antimony stockpile surged to $21.7M) and $11.3M net loss. Working capital fell $9.5M in quarter to $35M.
MD&A: Cash Flow verify on EDGAR → -
high
Antimony gross profit collapsed 58% to $1.0M as cost per pound jumped to $16.28 from $9.66, squeezing margin to $3.65/lb from $6.68/lb despite higher prices. Revenue down 6% on lower volumes.
MD&A: Antimony Operations verify on EDGAR → -
high
Awarded $27M Defense Production Act grant for antimony processing expansion; $16.2M obligated, $10.8M subject to future authorization. $12.8M approved for initial milestones. Funding contingent on milestone achievement and compliance.
Risk Factors & MD&A: Government Grant verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade UAMY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify